<!DOCTYPE html> <html class="govuk-template" lang="en">  <head><script type="text/javascript" src="/_static/js/bundle-playback.js?v=HxkREWBo" charset="utf-8"></script> <script type="text/javascript" src="/_static/js/wombat.js?v=txqj7nKC" charset="utf-8"></script> <script>window.RufflePlayer=window.RufflePlayer||{};window.RufflePlayer.config={"autoplay":"on","unmuteOverlay":"hidden"};</script> <script type="text/javascript" src="/_static/js/ruffle/ruffle.js"></script> <script type="text/javascript"> __wm.init("http://web.archive.org/web"); __wm.wombat("https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment","20221006143334","http://web.archive.org/","web","/_static/", "1665066814"); </script> <link rel="stylesheet" type="text/css" href="/_static/css/banner-styles.css?v=S1zqJCYt" /> <link rel="stylesheet" type="text/css" href="/_static/css/iconochive.css?v=3PDvdIFv" />  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"> <meta property="og:description" content=""> <meta property="og:title" content="Decision on Evusheld as a COVID-19 treatment"> <meta property="og:url" content="http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment"> <meta property="og:type" content="article"> <meta property="og:site_name" content="GOV.UK"> <meta name="twitter:card" content="summary"> <meta name="govuk:analytics:organisations" content="<D12>"> <meta name="govuk:primary-publishing-organisation" content="Department of Health and Social Care"> <meta name="govuk:public-updated-at" content="2022-10-04T14:04:11.000+00:00"> <meta name="govuk:updated-at" content="2022-10-06T13:00:09.018Z"> <meta name="govuk:first-published-at" content="2022-10-06T13:00:02.000+00:00"> <meta name="govuk:content-id" content="62464d98-ce53-4bde-980f-e542009770b9"> <meta name="govuk:schema-name" content="html_publication"> <meta name="govuk:rendering-app" content="government-frontend"> <meta name="govuk:publishing-app" content="whitehall"> <meta name="govuk:format" content="html_publication"> <meta charset="utf-8"> <title lang="en"> Decision on Evusheld as a COVID-19 treatment - GOV.UK </title> <script src="http://web.archive.org/web/20221006143334js_/https://www.gov.uk/assets/static/govuk_publishing_components/vendor/lux/lux-measurer-505eef3e243b1d08ea7c4b945ebe1ae146d896db61366e415b30cc1bcd84cbdc.js" async="async"></script> <script src="http://web.archive.org/web/20221006143334js_/https://www.gov.uk/assets/static/govuk_publishing_components/rum-loader-c53469dcb841d7b228c914a2e8bdcf3b831a578adf7d4f21cf9da5b85df7381e.js" async="async" data-lux-reporter-script="https://www.gov.uk/assets/static/govuk_publishing_components/vendor/lux/lux-reporter-0630526d2811f955ec5e421a6233bd828938bf706c2481233ef4efb8831d0625.js"></script> <link rel="stylesheet" href="http://web.archive.org/web/20221006143334cs_/https://www.gov.uk/assets/static/application-2c94784e6080dc2a919bfbcd48e30ff9f75b4d356fd013c0a32f49f29a467352.css" media="all"> <link rel="stylesheet" href="http://web.archive.org/web/20221006143334cs_/https://www.gov.uk/assets/static/print-2a680d506cc712d929abd0abaf49423a99f2cddc1b23a38c29014bc002f0f9dc.css" media="print">  <link rel="shortcut icon" href="http://web.archive.org/web/20221006143334im_/https://www.gov.uk/assets/static/favicon-9ed7849c462c53aa2cdf1690eb257e801ecbf5696d1d0928868c5b032b4adb36.ico" type="image/x-icon"> <link rel="mask-icon" href="http://web.archive.org/web/20221006143334im_/https://www.gov.uk/assets/static/govuk-mask-icon-a409a4db4a5e72c99ae3916653710064c43eb4be35821f79c07c5156e7dc5808.svg" color="#0b0c0c"> <link rel="apple-touch-icon" sizes="180x180" href="http://web.archive.org/web/20221006143334im_/https://www.gov.uk/assets/static/govuk-apple-touch-icon-180x180-026deaa34fa328ae5f1f519a37dbd15e6555c5086e1ba83986cd0827a7209902.png"> <link rel="apple-touch-icon" sizes="167x167" href="http://web.archive.org/web/20221006143334im_/https://www.gov.uk/assets/static/govuk-apple-touch-icon-167x167-a44a5b317f51a61950697fbe6c61ffe3b5acdd89de60ef70429daa32881d5279.png"> <link rel="apple-touch-icon" sizes="152x152" href="http://web.archive.org/web/20221006143334im_/https://www.gov.uk/assets/static/govuk-apple-touch-icon-152x152-828a839e5c83de19f98014eef54cec77aa11063a23ce321970d6f9310eeabb6c.png"> <link rel="apple-touch-icon" href="http://web.archive.org/web/20221006143334im_/https://www.gov.uk/assets/static/govuk-apple-touch-icon-5f801db05920bd1eb2b27a7a90328599bb16b6344c3213795af0f20d3ca179b0.png"> <meta name="theme-color" content="#0b0c0c"> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta property="og:image" content="http://web.archive.org/web/20221006143334im_/https://www.gov.uk/assets/static/govuk-opengraph-image-dade2dad5775023b0568381c4c074b86318194edb36d3d68df721eea7deeac4b.png"> <link rel="stylesheet" href="/web/20221006143334cs_/https://www.gov.uk/assets/government-frontend/application-69450ed4fc007ef22e313f1c73a1f02c3aba8f2eab45d754ce20b3c7eb538e4c.css"> <link rel="stylesheet" href="/web/20221006143334cs_/https://www.gov.uk/assets/government-frontend/print-bcb988c58a27d6eb2bbce8bdaa46a916550927b9715bd8bf8b69a36c3716d40f.css" media="print"> <link rel="canonical" href="http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment"> <meta name="govuk:rendering-application" content="government-frontend"> </head> <body class="gem-c-layout-for-public govuk-template__body"> <script> document.body.className = ((document.body.className) ? document.body.className + ' js-enabled' : 'js-enabled'); </script> <a class="gem-c-skip-link govuk-skip-link govuk-!-display-none-print" data-module="govuk-skip-link" href="#content">Skip to main content</a> <div id="global-cookie-message" class="gem-c-cookie-banner govuk-clearfix" data-module="cookie-banner" role="region" aria-label="cookie banner" data-nosnippet> <div class="govuk-cookie-banner js-banner-wrapper" role="region" aria-label="Cookies on GOV.UK"> <div class="gem-c-cookie-banner__message govuk-cookie-banner__message govuk-width-container"> <div class="govuk-grid-row"> <div class="govuk-grid-column-two-thirds"> <h2 class="govuk-cookie-banner__heading govuk-heading-m">Cookies on GOV.UK</h2> <div class="govuk-cookie-banner__content"> <p class="govuk-body">We use some essential cookies to make this website work.</p> <p class="govuk-body">We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.</p> <p class="govuk-body">We also use cookies set by other sites to help us deliver content from their services.</p> </div> </div> </div> <div class="govuk-button-group"> <button class="gem-c-button govuk-button" type="submit" data-module="gem-track-click" data-accept-cookies="true" data-track-category="cookieBanner" data-track-action="Cookie banner accepted" data-cookie-types="all">Accept additional cookies</button> <button class="gem-c-button govuk-button" type="submit" data-module="gem-track-click" data-reject-cookies="true" data-track-category="cookieBanner" data-track-action="Cookie banner rejected">Reject additional cookies</button> <a class="govuk-link" href="/web/20221006143334/https://www.gov.uk/help/cookies">View cookies</a> </div> </div> </div> <div class="gem-c-cookie-banner__confirmation govuk-width-container" tabindex="-1" hidden> <p class="gem-c-cookie-banner__confirmation-message" role="alert">You can <a class="govuk-link" data-module="gem-track-click" data-track-category="cookieBanner" data-track-action="Cookie banner settings clicked from confirmation" href="/web/20221006143334/https://www.gov.uk/help/cookies">change your cookie settings</a> at any time.</p> <div class="govuk-button-group"> <button class="gem-c-cookie-banner__hide-button govuk-button" data-hide-cookie-banner="true" data-module="gem-track-click" data-track-category="cookieBanner" data-track-action="Hide cookie banner">Hide this message</button> </div> </div> </div> <header role="banner" class="gem-c-layout-super-navigation-header" data-module="gem-track-click" data-track-links-only> <div class="gem-c-layout-super-navigation-header__container govuk-width-container govuk-clearfix"> <div class="gem-c-layout-super-navigation-header__header-logo"> <a class="govuk-header__link govuk-header__link--homepage" data-track-action="logoLink" data-track-category="headerClicked" data-track-label="https://www.gov.uk" data-track-dimension="GOV.UK" data-track-dimension-index="29" href="http://web.archive.org/web/20221006143334/https://www.gov.uk/" id="logo" title="Go to the GOV.UK homepage"> <span class="govuk-header__logotype">  <svg aria-hidden="true" class="govuk-header__logotype-crown gem-c-layout-super-navigation-header__logotype-crown" focusable="false" height="30" viewbox="0 0 132 97" width="36" xmlns="http://www.w3.org/2000/svg"> <path d="M25 30.2c3.5 1.5 7.7-.2 9.1-3.7 1.5-3.6-.2-7.8-3.9-9.2-3.6-1.4-7.6.3-9.1 3.9-1.4 3.5.3 7.5 3.9 9zM9 39.5c3.6 1.5 7.8-.2 9.2-3.7 1.5-3.6-.2-7.8-3.9-9.1-3.6-1.5-7.6.2-9.1 3.8-1.4 3.5.3 7.5 3.8 9zM4.4 57.2c3.5 1.5 7.7-.2 9.1-3.8 1.5-3.6-.2-7.7-3.9-9.1-3.5-1.5-7.6.3-9.1 3.8-1.4 3.5.3 7.6 3.9 9.1zm38.3-21.4c3.5 1.5 7.7-.2 9.1-3.8 1.5-3.6-.2-7.7-3.9-9.1-3.6-1.5-7.6.3-9.1 3.8-1.3 3.6.4 7.7 3.9 9.1zm64.4-5.6c-3.6 1.5-7.8-.2-9.1-3.7-1.5-3.6.2-7.8 3.8-9.2 3.6-1.4 7.7.3 9.2 3.9 1.3 3.5-.4 7.5-3.9 9zm15.9 9.3c-3.6 1.5-7.7-.2-9.1-3.7-1.5-3.6.2-7.8 3.7-9.1 3.6-1.5 7.7.2 9.2 3.8 1.5 3.5-.3 7.5-3.8 9zm4.7 17.7c-3.6 1.5-7.8-.2-9.2-3.8-1.5-3.6.2-7.7 3.9-9.1 3.6-1.5 7.7.3 9.2 3.8 1.3 3.5-.4 7.6-3.9 9.1zM89.3 35.8c-3.6 1.5-7.8-.2-9.2-3.8-1.4-3.6.2-7.7 3.9-9.1 3.6-1.5 7.7.3 9.2 3.8 1.4 3.6-.3 7.7-3.9 9.1zM69.7 17.7l8.9 4.7V9.3l-8.9 2.8c-.2-.3-.5-.6-.9-.9L72.4 0H59.6l3.5 11.2c-.3.3-.6.5-.9.9l-8.8-2.8v13.1l8.8-4.7c.3.3.6.7.9.9l-5 15.4v.1c-.2.8-.4 1.6-.4 2.4 0 4.1 3.1 7.5 7 8.1h.2c.3 0 .7.1 1 .1.4 0 .7 0 1-.1h.2c4-.6 7.1-4.1 7.1-8.1 0-.8-.1-1.7-.4-2.4V34l-5.1-15.4c.4-.2.7-.6 1-.9zM66 92.8c16.9 0 32.8 1.1 47.1 3.2 4-16.9 8.9-26.7 14-33.5l-9.6-3.4c1 4.9 1.1 7.2 0 10.2-1.5-1.4-3-4.3-4.2-8.7L108.6 76c2.8-2 5-3.2 7.5-3.3-4.4 9.4-10 11.9-13.6 11.2-4.3-.8-6.3-4.6-5.6-7.9 1-4.7 5.7-5.9 8-.5 4.3-8.7-3-11.4-7.6-8.8 7.1-7.2 7.9-13.5 2.1-21.1-8 6.1-8.1 12.3-4.5 20.8-4.7-5.4-12.1-2.5-9.5 6.2 3.4-5.2 7.9-2 7.2 3.1-.6 4.3-6.4 7.8-13.5 7.2-10.3-.9-10.9-8-11.2-13.8 2.5-.5 7.1 1.8 11 7.3L80.2 60c-4.1 4.4-8 5.3-12.3 5.4 1.4-4.4 8-11.6 8-11.6H55.5s6.4 7.2 7.9 11.6c-4.2-.1-8-1-12.3-5.4l1.4 16.4c3.9-5.5 8.5-7.7 10.9-7.3-.3 5.8-.9 12.8-11.1 13.8-7.2.6-12.9-2.9-13.5-7.2-.7-5 3.8-8.3 7.1-3.1 2.7-8.7-4.6-11.6-9.4-6.2 3.7-8.5 3.6-14.7-4.6-20.8-5.8 7.6-5 13.9 2.2 21.1-4.7-2.6-11.9.1-7.7 8.8 2.3-5.5 7.1-4.2 8.1.5.7 3.3-1.3 7.1-5.7 7.9-3.5.7-9-1.8-13.5-11.2 2.5.1 4.7 1.3 7.5 3.3l-4.7-15.4c-1.2 4.4-2.7 7.2-4.3 8.7-1.1-3-.9-5.3 0-10.2l-9.5 3.4c5 6.9 9.9 16.7 14 33.5 14.8-2.1 30.8-3.2 47.7-3.2z" fill="currentColor" fill-rule="evenodd"> </path> </svg>   <span class="govuk-header__logotype-text"> GOV.UK </span> </span> </a> </div> <nav aria-labelledby="super-navigation-menu-heading" class="gem-c-layout-super-navigation-header__content" data-module="super-navigation-mega-menu"> <h2 id="super-navigation-menu-heading" class="govuk-visually-hidden"> Navigation menu </h2> <button aria-controls="super-navigation-menu" aria-expanded="true" aria-label="Hide navigation menu" class="gem-c-layout-super-navigation-header__navigation-top-toggle-button" data-text-for-hide="Hide navigation menu" data-text-for-show="Show navigation menu" data-toggle-desktop-group="hidden" data-toggle-mobile-group="top" data-tracking-key="menu" hidden id="super-navigation-menu-toggle" type="button"> <span class="gem-c-layout-super-navigation-header__navigation-top-toggle-button-inner"> Menu </span> </button> <ul id="super-navigation-menu" class="gem-c-layout-super-navigation-header__navigation-items"> <li class="gem-c-layout-super-navigation-header__navigation-item gem-c-layout-super-navigation-header__navigation-item--with-children"> <div class="gem-c-layout-super-navigation-header__navigation-toggle-wrapper govuk-clearfix"> <a class="gem-c-layout-super-navigation-header__navigation-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse" data-track-dimension="Topics" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse"> <span class="gem-c-layout-super-navigation-header__navigation-item-link-inner"> Topics </span> </a> <button aria-controls="super-navigation-menu__section-c77113f7" aria-expanded="false" aria-label="Show Topics menu" class="gem-c-layout-super-navigation-header__navigation-second-toggle-button" data-text-for-hide="Hide Topics menu" data-text-for-show="Show Topics menu" data-toggle-desktop-group="top" data-toggle-mobile-group="second" data-tracking-key="topics" hidden="hidden" id="super-navigation-menu__section-c77113f7-toggle" type="button"> <span class="gem-c-layout-super-navigation-header__navigation-second-toggle-button-inner">Topics</span> </button> </div> <div hidden class="gem-c-layout-super-navigation-header__navigation-dropdown-menu" id="super-navigation-menu__section-c77113f7"> <div class="govuk-width-container gem-c-layout-super-navigation-header__width-container"> <div class="govuk-grid-row"> <div class="govuk-grid-column-one-third-from-desktop"> <h3 class="govuk-body-l gem-c-layout-super-navigation-header__menu-description"> Find information and services </h3> </div> <div class="govuk-grid-column-two-thirds-from-desktop"> <ul class="gem-c-layout-super-navigation-header__navigation-second-items gem-c-layout-super-navigation-header__navigation-second-items--topics"> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/benefits" data-track-dimension="Benefits" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/benefits">Benefits</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/births-deaths-marriages" data-track-dimension="Births, death, marriages and care" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/births-deaths-marriages">Births, death, marriages and care</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/business" data-track-dimension="Business and self-employed" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/business">Business and self-employed</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/childcare-parenting" data-track-dimension="Childcare and parenting" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/childcare-parenting">Childcare and parenting</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/citizenship" data-track-dimension="Citizenship and living in the UK" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/citizenship">Citizenship and living in the UK</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/cost-of-living" data-track-dimension="Cost of living support" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/cost-of-living">Cost of living support</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/justice" data-track-dimension="Crime, justice and the law" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/justice">Crime, justice and the law</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/disabilities" data-track-dimension="Disabled people" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/disabilities">Disabled people</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/driving" data-track-dimension="Driving and transport" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/driving">Driving and transport</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/education" data-track-dimension="Education and learning" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/education">Education and learning</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/employing-people" data-track-dimension="Employing people" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/employing-people">Employing people</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/environment-countryside" data-track-dimension="Environment and countryside" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/environment-countryside">Environment and countryside</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/housing-local-services" data-track-dimension="Housing and local services" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/housing-local-services">Housing and local services</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/tax" data-track-dimension="Money and tax" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/tax">Money and tax</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/abroad" data-track-dimension="Passports, travel and living abroad" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/abroad">Passports, travel and living abroad</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/visas-immigration" data-track-dimension="Visas and immigration" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/visas-immigration">Visas and immigration</a> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link" data-track-action="topicsLink" data-track-category="headerClicked" data-track-label="/browse/working" data-track-dimension="Working, jobs and pensions" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/browse/working">Working, jobs and pensions</a> </li> </ul> </div> </div> </div> </div> </li> <li class="gem-c-layout-super-navigation-header__navigation-item gem-c-layout-super-navigation-header__navigation-item--with-children"> <div class="gem-c-layout-super-navigation-header__navigation-toggle-wrapper govuk-clearfix"> <a class="gem-c-layout-super-navigation-header__navigation-item-link" data-track-action="governmentactivityLink" data-track-category="headerClicked" data-track-label="/search/news-and-communications" data-track-dimension="Government activity" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/search/news-and-communications"> <span class="gem-c-layout-super-navigation-header__navigation-item-link-inner"> Government activity </span> </a> <button aria-controls="super-navigation-menu__section-5b7b287e" aria-expanded="false" aria-label="Show Government activity menu" class="gem-c-layout-super-navigation-header__navigation-second-toggle-button" data-text-for-hide="Hide Government activity menu" data-text-for-show="Show Government activity menu" data-toggle-desktop-group="top" data-toggle-mobile-group="second" data-tracking-key="governmentactivity" hidden="hidden" id="super-navigation-menu__section-5b7b287e-toggle" type="button"> <span class="gem-c-layout-super-navigation-header__navigation-second-toggle-button-inner">Government activity</span> </button> </div> <div hidden class="gem-c-layout-super-navigation-header__navigation-dropdown-menu" id="super-navigation-menu__section-5b7b287e"> <div class="govuk-width-container gem-c-layout-super-navigation-header__width-container"> <div class="govuk-grid-row"> <div class="govuk-grid-column-one-third-from-desktop"> <h3 class="govuk-body-l gem-c-layout-super-navigation-header__menu-description"> Search for a department and find out what the government is doing </h3> </div> <div class="govuk-grid-column-two-thirds-from-desktop"> <ul class="gem-c-layout-super-navigation-header__navigation-second-items gem-c-layout-super-navigation-header__navigation-second-items--government-activity"> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link gem-c-layout-super-navigation-header__navigation-second-item-link--with-description" data-track-action="governmentactivityLink" data-track-category="headerClicked" data-track-label="/government/organisations" data-track-dimension="Departments" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/government/organisations">Departments</a> <p class="gem-c-layout-super-navigation-header__navigation-second-item-description">Departments, agencies and public bodies</p> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link gem-c-layout-super-navigation-header__navigation-second-item-link--with-description" data-track-action="governmentactivityLink" data-track-category="headerClicked" data-track-label="/search/news-and-communications" data-track-dimension="News" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/search/news-and-communications">News</a> <p class="gem-c-layout-super-navigation-header__navigation-second-item-description">News stories, speeches, letters and notices</p> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link gem-c-layout-super-navigation-header__navigation-second-item-link--with-description" data-track-action="governmentactivityLink" data-track-category="headerClicked" data-track-label="/search/guidance-and-regulation" data-track-dimension="Guidance and regulation" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/search/guidance-and-regulation">Guidance and regulation</a> <p class="gem-c-layout-super-navigation-header__navigation-second-item-description">Detailed guidance, regulations and rules</p> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link gem-c-layout-super-navigation-header__navigation-second-item-link--with-description" data-track-action="governmentactivityLink" data-track-category="headerClicked" data-track-label="/search/research-and-statistics" data-track-dimension="Research and statistics" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/search/research-and-statistics">Research and statistics</a> <p class="gem-c-layout-super-navigation-header__navigation-second-item-description">Reports, analysis and official statistics</p> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link gem-c-layout-super-navigation-header__navigation-second-item-link--with-description" data-track-action="governmentactivityLink" data-track-category="headerClicked" data-track-label="/search/policy-papers-and-consultations" data-track-dimension="Policy papers and consultations" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/search/policy-papers-and-consultations">Policy papers and consultations</a> <p class="gem-c-layout-super-navigation-header__navigation-second-item-description">Consultations and strategy</p> </li> <li class="gem-c-layout-super-navigation-header__dropdown-list-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-item-link gem-c-layout-super-navigation-header__navigation-second-item-link--with-description" data-track-action="governmentactivityLink" data-track-category="headerClicked" data-track-label="/search/transparency-and-freedom-of-information-releases" data-track-dimension="Transparency" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/search/transparency-and-freedom-of-information-releases">Transparency</a> <p class="gem-c-layout-super-navigation-header__navigation-second-item-description">Data, Freedom of Information releases and corporate reports</p> </li> </ul> <hr class="gem-c-layout-super-navigation-header__navigation-second-footer-break govuk-section-break govuk-section-break--visible"> <ul class="gem-c-layout-super-navigation-header__navigation-second-footer-list"> <li class="gem-c-layout-super-navigation-header__navigation-second-footer-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-footer-link" data-track-action="governmentactivityLink" data-track-category="headerClicked" data-track-label="/government/how-government-works" data-track-dimension="How government works" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/government/how-government-works">How government works</a> </li> <li class="gem-c-layout-super-navigation-header__navigation-second-footer-item"> <a class="govuk-link gem-c-layout-super-navigation-header__navigation-second-footer-link" data-track-action="governmentactivityLink" data-track-category="headerClicked" data-track-label="/government/get-involved" data-track-dimension="Get involved" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/government/get-involved">Get involved</a> </li> </ul> </div> </div> </div> </div> </li> </ul> <button aria-controls="super-search-menu" aria-expanded="true" aria-label="Hide search menu" class="gem-c-layout-super-navigation-header__search-toggle-button" data-text-for-hide="Hide search menu" data-text-for-show="Show search menu" data-toggle-mobile-group="top" data-toggle-desktop-group="top" data-tracking-key="search" hidden id="super-search-menu-toggle" type="button"> <span class="govuk-visually-hidden"> Search GOV.UK </span> <svg class="gem-c-layout-super-navigation-header__search-toggle-button-link-icon" width="27" height="27" viewbox="0 0 27 27" fill="none" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false"> <circle cx="12.0161" cy="11.0161" r="8.51613" stroke="currentColor" stroke-width="3"></circle> <line x1="17.8668" y1="17.3587" x2="26.4475" y2="25.9393" stroke="currentColor" stroke-width="3"></line> </svg> <span aria-hidden="true" class="gem-c-layout-super-navigation-header__navigation-top-toggle-close-icon" focusable="false"> × </span> </button> <div id="super-search-menu" class="gem-c-layout-super-navigation-header__search-items"> <h3 class="govuk-visually-hidden"> Search </h3> <div class="gem-c-layout-super-navigation-header__search-item"> <a class="gem-c-layout-super-navigation-header__search-item-link" href="/web/20221006143334/https://www.gov.uk/search"> <span class="gem-c-layout-super-navigation-header__search-item-link-text"> Search GOV.UK </span> <svg class="gem-c-layout-super-navigation-header__search-item-link-icon" width="27" height="27" viewbox="0 0 27 27" fill="none" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false"> <circle cx="10.0161" cy="10.0161" r="8.51613" stroke="currentColor" stroke-width="3"></circle> <line x1="15.8668" y1="16.3587" x2="25.4475" y2="25.9393" stroke="currentColor" stroke-width="3"></line> </svg> </a> </div> <div class="govuk-width-container gem-c-layout-super-navigation-header__search-and-popular"> <div class="govuk-grid-row"> <div class="govuk-grid-column-full"> <form class="gem-c-layout-super-navigation-header__search-form" id="search" action="/web/20221006143334/https://www.gov.uk/search" method="get" role="search" aria-label="Site-wide"> <div class="gem-c-search govuk-!-display-none-print gem-c-search--large gem-c-search--on-white gem-c-search--separate-label" data-module="gem-toggle-input-class-on-focus"> <label for="search-main-bbc7e803" class="govuk-label govuk-label--m">Search GOV.UK</label> <div class="gem-c-search__item-wrapper"> <input enterkeyhint="search" class="gem-c-search__item gem-c-search__input js-class-toggle" id="search-main-bbc7e803" name="q" title="Search" type="search" value=""> <div class="gem-c-search__item gem-c-search__submit-wrapper"> <button class="gem-c-search__submit" type="submit" data-track-category="headerClicked" data-track-action="searchSubmitted" data-track-label="/search/all" data-track-dimension="Search on GOV.UK" data-track-dimension-index="29" data-module="gem-track-click" enterkeyhint="search"> Search <svg class="gem-c-search__icon" width="27" height="27" viewbox="0 0 27 27" fill="none" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false"> <circle cx="12.0161" cy="11.0161" r="8.51613" stroke="currentColor" stroke-width="3"></circle> <line x1="17.8668" y1="17.3587" x2="26.4475" y2="25.9393" stroke="currentColor" stroke-width="3"></line> </svg> </button> </div> </div> </div> </form> </div> </div> <div class="govuk-grid-row"> <div class="govuk-grid-column-full"> <h3 class="govuk-heading-m">Popular on GOV.UK</h3> <ul class="govuk-list"> <li class="gem-c-layout-super-navigation-header__popular-item"> <a class="govuk-link gem-c-layout-super-navigation-header__popular-link" data-track-action="popularLink" data-track-category="headerClicked" data-track-label="/check-benefits-financial-support" data-track-dimension="Check benefits and financial support you can get" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/check-benefits-financial-support">Check benefits and financial support you can get</a> </li> <li class="gem-c-layout-super-navigation-header__popular-item"> <a class="govuk-link gem-c-layout-super-navigation-header__popular-link" data-track-action="popularLink" data-track-category="headerClicked" data-track-label="/government/publications/energy-bills-support/energy-bills-support-factsheet-8-september-2022" data-track-dimension="Limits on energy prices: Energy Price Guarantee" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/government/publications/energy-bills-support/energy-bills-support-factsheet-8-september-2022">Limits on energy prices: Energy Price Guarantee</a> </li> <li class="gem-c-layout-super-navigation-header__popular-item"> <a class="govuk-link gem-c-layout-super-navigation-header__popular-link" data-track-action="popularLink" data-track-category="headerClicked" data-track-label="/find-a-job" data-track-dimension="Find a job" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/find-a-job">Find a job</a> </li> <li class="gem-c-layout-super-navigation-header__popular-item"> <a class="govuk-link gem-c-layout-super-navigation-header__popular-link" data-track-action="popularLink" data-track-category="headerClicked" data-track-label="/coronavirus" data-track-dimension="Coronavirus (COVID-19)" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/coronavirus">Coronavirus (COVID-19)</a> </li> <li class="gem-c-layout-super-navigation-header__popular-item"> <a class="govuk-link gem-c-layout-super-navigation-header__popular-link" data-track-action="popularLink" data-track-category="headerClicked" data-track-label="/sign-in-universal-credit" data-track-dimension="Universal Credit account: sign in" data-track-dimension-index="29" href="/web/20221006143334/https://www.gov.uk/sign-in-universal-credit">Universal Credit account: sign in</a> </li> </ul> </div> </div> </div> </div> </nav> </div> </header> <div class="gem-c-layout-for-public__blue-bar govuk-width-container"></div> <div id="wrapper" class="direction-ltr govuk-width-container"> <div class="gem-c-contextual-breadcrumbs"> <div class="gem-c-breadcrumbs govuk-breadcrumbs govuk-breadcrumbs--collapse-on-mobile" data-module="gem-track-click"> <ol class="govuk-breadcrumbs__list"> <li class="govuk-breadcrumbs__list-item"> <a data-track-category="homeLinkClicked" data-track-action="homeBreadcrumb" data-track-label="" data-track-options="{}" class="govuk-breadcrumbs__link" href="/web/20221006143334/https://www.gov.uk/">Home</a> </li> <li class="govuk-breadcrumbs__list-item"> <a data-track-category="breadcrumbClicked" data-track-action="2" data-track-label="/coronavirus-taxon" data-track-options="{"dimension28":"4","dimension29":"Coronavirus (COVID-19)"}" class="govuk-breadcrumbs__link" href="/web/20221006143334/https://www.gov.uk/coronavirus-taxon">Coronavirus (COVID-19)</a> </li> <li class="govuk-breadcrumbs__list-item"> <a data-track-category="breadcrumbClicked" data-track-action="3" data-track-label="/coronavirus-taxon/health-and-wellbeing" data-track-options="{"dimension28":"4","dimension29":"Health and wellbeing during coronavirus"}" class="govuk-breadcrumbs__link" href="/web/20221006143334/https://www.gov.uk/coronavirus-taxon/health-and-wellbeing">Health and wellbeing during coronavirus</a> </li> <li class="govuk-breadcrumbs__list-item"> <a data-track-category="breadcrumbClicked" data-track-action="4" data-track-label="/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups" data-track-options="{"dimension28":"4","dimension29":"Decision on Evusheld as a coronavirus (COVID-19) treatment: letter to patient groups"}" class="govuk-breadcrumbs__link" href="/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups">Decision on Evusheld as a coronavirus (COVID-19) treatment: letter to patient groups</a> </li> </ol> </div> </div> <main role="main" id="content" class="html-publication" lang="en"> <div class="publication-external"> <ul class="organisation-logos"> <li class="organisation-logos__logo"> <div class="gem-c-organisation-logo brand--department-of-health"> <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/web/20221006143334/https://www.gov.uk/government/organisations/department-of-health-and-social-care"> <span class="gem-c-organisation-logo__name">Department<br>of Health &<br>Social Care</span> </a> </div> </li> </ul> </div> <header class="gem-c-inverse-header gem-c-inverse-header--padding-top "> <div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0"> <span class="govuk-caption-xl gem-c-title__context"> Correspondence </span> <h1 class="gem-c-title__text govuk-heading-xl"> Decision on Evusheld as a COVID-19 treatment </h1> </div> <p class="publication-header__last-changed">Published 6 October 2022</p> </header> <div class="sidebar-with-body" id="contents"> <div class="govuk-grid-row"> <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container"> <nav class="gem-c-contents-list" aria-label="Contents" role="navigation" data-module="gem-track-click"> <h2 class="gem-c-contents-list__title"> Contents </h2> <ol class="gem-c-contents-list__list"> <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered"> <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#government-decision-on-evusheld" data-track-options="{"dimension29":"Government decision on Evusheld"}" href="#government-decision-on-evusheld">Government decision on Evusheld</a> </li> <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered"> <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#annex-a" data-track-options="{"dimension29":"Annex A"}" href="#annex-a">Annex A</a> </li> <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered"> <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#annex-b" data-track-options="{"dimension29":"Annex B"}" href="#annex-b">Annex B</a> </li> </ol> </nav> <div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6"> <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="ga4-event-tracker print-link" data-ga4="{"event_name":"print_page","type":"Print this page","index":1,"index_total":1,"section":"Contents"}">Print this page</button> </div> </div> <div class="print-wrapper"> <div class="print-meta-data"> <p> <img class="print-meta-data-licence" src="/web/20221006143334im_/https://www.gov.uk/assets/government-frontend/open-government-licence-min-93b6a51b518ff99714a1aa2a7d2162735c155ec3cb073c75fb88b2a332fa83d3.png"> </p> <p> © Crown copyright 2022 </p> <p> This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="http://web.archive.org/web/20221006143334/https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="http://web.archive.org/web/20221006143334/mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>. </p> <p> Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. </p> <p> This publication is available at https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment </p> </div> </div> <div class="main-content-container"> <div class="gem-c-govspeak-html-publication"> <div class="gem-c-govspeak govuk-govspeak " data-module="govspeak"> <div class="govspeak"> <h2 id="government-decision-on-evusheld">Government decision on Evusheld</h2> <p>Thank you for your letters of <a rel="external" href="http://web.archive.org/web/20221006143334/https://bloodcancer.org.uk/news/leading-charities-and-clinicians-urge-government-to-secure-evusheld/" class="govuk-link">28 July</a> and <a rel="external" href="http://web.archive.org/web/20221006143334/https://media.bloodcancer.org.uk/documents/Evusheld_Letter_to_Barclay_23.08.22.pdf" class="govuk-link">23 August 2022</a> on Evusheld.</p> <p>I understand your concerns and would like to assure you that government efforts remain absolutely focused on protecting the most vulnerable, including through prioritised access to vaccines, treatments and testing.</p> <p>The expert panel who advises government has made clear that there is insufficient evidence available at this time to support procurement and deployment of Evusheld through emergency procedures.</p> <p>When the Medicines and Healthcare products Regulatory Agency (<abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>) gave conditional marketing authorisation to Evusheld on 17 March 2022, following trials conducted during the Delta wave of the coronavirus (COVID-19) pandemic, it noted a lack of data regarding dose and efficacy against Omicron.</p> <p>A number of other countries’ regulatory authorities, including the European Medicines Agency and the US Food and Drug Administration, have noted similar issues, although many of those countries who had already procured Evusheld have decided to continue using it, in most cases doubling the dose to 600mg.</p> <p>There have been similar concerns about the effectiveness of other monoclonal antibodies to emerging COVID-19 variants, on the basis of in vitro (laboratory) testing, leading to appropriate re-evaluation prior to recommendation for widespread deployment or continuation of use. In some instances, the in vitro data has been so unequivocal in demonstrating lack of effectiveness that a product has been promptly withdrawn – in the case of Evusheld, a number of different groups have conducted laboratory tests with different Omicron sub-variants and there is ongoing uncertainty about how these results might translate to clinical effectiveness.</p> <p>To address your specific questions, the decision has been made not to procure Evusheld at this time drawing on expert advice from the <a rel="external" href="http://web.archive.org/web/20221006143334/https://www.nice.org.uk/covid-19/rapid-c19" class="govuk-link">research to access pathway for investigational drugs for COVID-19 (<abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr>)</a> Oversight Group and a UK national expert policy working group as well as Department of Health and Social Care (<abbr title="Department of Health and Social Care">DHSC</abbr>) officials, all of whom have collectively concluded that there is insufficient evidence of benefit to recommend deployment at this time. In their expert advice, <abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr> note that:</p> <blockquote> <p class="last-child">the risks of proceeding to patient access are considered to outweigh the risks of not providing this treatment in the current pandemic context.</p> </blockquote> <p>More detail on <abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr> can be found in Annex A.</p> <p><abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr> has considered the evidence base for Evusheld 11 times in 18 months, starting in February 2021, and is keeping it under active review, including through monitoring the emerging data. They have considered a full range of evidence, including clinical trial data, in vitro analysis and all the observational studies in the appendix to your letter of 23 August 2022.</p> <p>As the authors note themselves, there are limitations to these studies.</p> <p>For example, Young-Xu and others state:</p> <blockquote> <p class="last-child">results may not be generalizable to a larger population of patients.</p> </blockquote> <p>Kertes and others state:</p> <blockquote> <p class="last-child">the study did not take into account differences between the 2 groups regarding other antiviral treatments available, such as nirmatrelvir, that may also affect severe disease prevalence.</p> </blockquote> <p>And Jurdi and others state:</p> <blockquote> <p class="last-child">The limitations of our study include its observational nature, retrospective design, lack of ability to detect asymptomatic breakthrough infections and possible differences between the tixagevimab/cilgavimab and control groups that could have influenced the rate of breakthrough infection.</p> </blockquote> <p>In addition to the inherent limitations of observational data – particularly on small sample sizes – it should also be noted that most of these studies are pre-prints (therefore have not been scrutinised through peer review). There are also concerns with the methodology of a number of studies, as it is not clear that the comparator group is adequately matched (such that the Evusheld group may be at inherently lower risk of adverse outcomes), or where the follow-up period is substantially shorter for the Evusheld group compared with the control group (such that the Evusheld group would have had a shorter time to experience a COVID-19 infection).</p> <p>So, while some of the findings may appear encouraging, the view from our experts remains that the methodological and reporting limitations of these papers means there is insufficient evidence from the clinical data to recommend deployment at this time.</p> <p>The Chief Medical Officer is content that the correct process for providing clinical advice has been followed and agrees that Evusheld should now be appraised by the National Institute for Health and Care Excellence (<abbr title="National Institute for Health and Care Excellence">NICE</abbr>) following the usual process for drugs being made available to NHS patients.</p> <p>In terms of the patients who stand to benefit from a safe and effective prophylactic, your letter refers to 500,000 immunosuppressed people in the UK. Notwithstanding the questions on efficacy and duration of effect, it is highly unlikely that supply could be made available to the UK for all these patients in autumn or winter 2022, particularly as doubling the dose to 600mg is recommended for use against Omicron.</p> <p>Moreover, it is also unlikely to be suitable or needed for this size of cohort. Evidence shows that different patient groups with immunosuppression have different levels of vaccine response. Identifying the correct cohorts (for example those with unpredictable, low or no antibody response) would be essential, even if questions on effectiveness were sufficiently answered.</p> <p>Evusheld is not necessary for those patients who have a protective antibody response to COVID-19 vaccination. In order to understand better who within this group mounts a vaccine response, we are exploring the possibility of piloting a programme to test antibody levels in immunosuppressed patients. This could help develop a more accurate understanding of potential cohorts for prophylactic treatments in future and provide reassurance to some patients by identifying any who have mounted a protective antibody response following vaccination. Officials will follow up with patient groups separately to seek input into the development of this potential programme.</p> <p>In order to gain further evidence, our clinical advisers have also recommended a trial is considered as a route to answering outstanding questions on the link between in vitro tests and clinical outcomes for current and future variants, which is currently not known, together with evaluating the effectiveness and safety of a dose of 600mg, as this was not tested in the randomised controlled trials.</p> <p>I personally met senior AstraZeneca leaders on Thursday 18 August 2022, and the <abbr title="Department of Health and Social Care">DHSC</abbr> Chief Scientific Adviser has had frequent discussions with science leaders in AstraZeneca, including a meeting on Friday 26 August 2022 to discuss data from existing observational studies in detail. We remain committed to close working with the company, and I greatly value the continued partnership we share with AstraZeneca and recognise the very positive impact they have made throughout the pandemic and beyond.</p> <p>Yours,</p> <p>Rt Hon Steve Barclay MP</p> <h2 id="annex-a">Annex A</h2> <h3 id="about-rapid-c-19">About <abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr> </h3> <p><a rel="external" href="http://web.archive.org/web/20221006143334/https://www.nice.org.uk/covid-19/rapid-c19" class="govuk-link"><abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr></a> is a multi-agency initiative set up in response to the pandemic that aims to get treatments for COVID-19 to NHS patients quickly and safely. Its membership includes the UK’s main healthcare agencies including:</p> <ul> <li><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr></li> <li><abbr title="National Institute for Health and Care Excellence">NICE</abbr></li> <li>NHS England (<abbr title="NHS England">NHSE</abbr>) and the NHS</li> <li>National Institute for Health Research (<abbr title="National Institute for Health Research">NIHR</abbr>)</li> <li>the devolved governments</li> </ul> <p>The NHS had overall responsibility for establishing <abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr>, and <abbr title="National Institute for Health and Care Excellence">NICE</abbr> chairs the Senior <abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr> Oversight Group and provides secretariat support.</p> <p>As of June 2022, <abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr> had around 90 topics in active monitoring and the oversight group has considered the evidence in detail for those drugs that have evidence of benefit, since it was stood up in April 2020. Of these, 9 have led to a positive recommendation to the 4 UK Chief Medical Officers that direct deployment outside of the more normal processes should be considered.</p> <h3 id="reporting">Reporting</h3> <p><abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr> is a multi-agency initiative including <abbr title="National Institute for Health Research">NIHR</abbr>, <abbr title="National Institute for Health and Care Excellence">NICE</abbr>, <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>, <abbr title="NHS England">NHSE</abbr> and representatives from the devolved governments. The agencies aim to ensure safe and timely patient access to treatments that show evidence of benefit in preventing and treating COVID-19.</p> <p>Where good evidence of efficacy of a treatment is sufficient for further action to be taken, the oversight group’s assessment of the evidence and suggested next steps are summarised in a briefing to the Chief Medical Officer.</p> <h3 id="expert-working-group">Expert working group</h3> <p>In parallel to the formation of <abbr title="research to access pathway for investigational drugs for COVID-19">RAPID C-19</abbr>, <abbr title="NHS England">NHSE</abbr> extended its existing national clinical policy-making process to cover COVID-19 therapeutics. As part of this process, a national expert working group (<abbr title="expert working group">EWG</abbr>) was created to support development of a national clinical policy with a focus on clinical effectiveness and eligibility criteria.</p> <p>An <abbr title="expert working group">EWG</abbr> is convened to develop a national clinical policy for a specific drug or sometimes to provide further relevant advice. The <abbr title="expert working group">EWG</abbr> is chaired by a senior NHS staff member, and the membership includes UK-wide national experts and frontline clinicians. Officials from the devolved governments are also involved throughout.</p> <p>EWGs have focused on therapeutic agents but, more recently, have also considered prophylactic agents.</p> <h2 id="annex-b">Annex B</h2> <h3 id="nice-appraisal-process"> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> appraisal process</h3> <p><abbr title="National Institute for Health and Care Excellence">NICE</abbr> provides evidence-based, rigorous evaluation of the clinical and cost effectiveness of medicines for use in the NHS.</p> <p><abbr title="National Institute for Health and Care Excellence">NICE</abbr> began consulting stakeholders on the draft scope for an evaluation of the clinical and cost effectiveness of Evusheld for preventing COVID-19 in July 2022, and it was formally referred to <abbr title="National Institute for Health and Care Excellence">NICE</abbr> by <abbr title="Department of Health and Social Care">DHSC</abbr> on 10 August 2022. The <abbr title="National Institute for Health and Care Excellence">NICE</abbr> appraisal has begun this month with draft guidance expected in April 2023.</p> <p><abbr title="National Institute for Health and Care Excellence">NICE</abbr>, in discussion with AstraZeneca, has taken steps to expedite the appraisal process by bringing forward the deadline for the company’s evidence submission so that it is able to issue guidance to the NHS as quickly as possible.</p> <p><a rel="external" href="http://web.archive.org/web/20221006143334/https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/process" class="govuk-link">Learn more about the <abbr title="National Institute for Health and Care Excellence">NICE</abbr> technology appraisal process.</a></p> <p>More detailed information on the Evusheld appraisal process will be provided on <abbr title="National Institute for Health and Care Excellence">NICE</abbr>’s website shortly.</p> </div> </div> </div> </div> </div> <div class="govuk-grid-row"> <a class="govuk-link app-c-back-to-top dont-print" href="#contents"> <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17" aria-hidden="true" focusable="false"> <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path> </svg> Back to top </a> </div> </div> </main> </div> <div class="govuk-width-container"> <div class="gem-c-feedback govuk-!-display-none-print" data-module="feedback ga4-event-tracker"> <div class="gem-c-feedback__prompt gem-c-feedback__js-show js-prompt" tabindex="-1"> <div class="gem-c-feedback__prompt-questions js-prompt-questions" hidden> <h2 class="gem-c-feedback__prompt-question">Is this page useful?</h2> <ul class="gem-c-feedback__option-list"> <li class="gem-c-feedback__option-list-item govuk-visually-hidden" style="display: none" hidden> <a class="gem-c-feedback__prompt-link" data-track-category="yesNoFeedbackForm" data-track-action="ffMaybeClick" role="button" style="display: none" hidden="hidden" aria-hidden="true" href="/web/20221006143334/https://www.gov.uk/contact/govuk"> Maybe </a> </li> <li class="gem-c-feedback__option-list-item"> <button class="govuk-button gem-c-feedback__prompt-link js-page-is-useful" data-track-category="yesNoFeedbackForm" data-track-action="ffYesClick" data-ga4="{"event_name":"form_submit","type":"feedback","text":"Yes", "section": "Is this page useful?"}"> Yes <span class="govuk-visually-hidden">this page is useful</span> </button> </li> <li class="gem-c-feedback__option-list-item"> <button class="govuk-button gem-c-feedback__prompt-link js-toggle-form js-page-is-not-useful" data-track-category="yesNoFeedbackForm" data-track-action="ffNoClick" aria-controls="page-is-not-useful" aria-expanded="false" data-ga4="{"event_name":"form_submit","type":"feedback","text":"No", "section": "Is this page useful?"}"> No <span class="govuk-visually-hidden">this page is not useful</span> </button> </li> </ul> </div> <div class="gem-c-feedback__prompt-questions gem-c-feedback__prompt-success js-prompt-success" role="alert" hidden> Thank you for your feedback </div> <div class="gem-c-feedback__prompt-questions gem-c-feedback__prompt-questions--something-is-wrong js-prompt-questions" hidden> <button class="govuk-button gem-c-feedback__prompt-link js-toggle-form js-something-is-wrong" data-track-category="Onsite Feedback" data-track-action="GOV-UK Open Form" aria-controls="something-is-wrong" aria-expanded="false"> Report a problem with this page </button> </div> </div> <form action="/web/20221006143334/https://www.gov.uk/contact/govuk/problem_reports" id="something-is-wrong" class="gem-c-feedback__form js-feedback-form" data-track-category="Onsite Feedback" data-track-action="GOV.UK Send Form" method="post" hidden> <button class="govuk-button govuk-button--secondary gem-c-feedback__close gem-c-feedback__js-show js-close-form" data-track-category="Onsite Feedback" data-track-action="GOV.UK Close Form" aria-controls="something-is-wrong" aria-expanded="true"> Close </button> <div class="govuk-grid-row"> <div class="govuk-grid-column-two-thirds"> <div class="gem-c-feedback__error-summary gem-c-feedback__js-show js-errors" tabindex="-1" hidden></div> <input type="hidden" name="url" value="https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment"> <h3 class="gem-c-feedback__form-heading">Help us improve GOV.UK</h3> <p id="feedback_explanation" class="gem-c-feedback__form-paragraph">Don’t include personal or financial information like your National Insurance number or credit card details.</p> <div class="govuk-visually-hidden" aria-hidden="true"> <label for="giraffe">This field is for robots only. Please leave blank</label> <input id="giraffe" name="giraffe" type="text" pattern=".{0}" tabindex="-1" autocomplete="off"> </div> <div class="gem-c-textarea govuk-form-group govuk-!-margin-bottom-6"> <label for="textarea-a367d1cf" class="gem-c-label govuk-label">What were you doing?</label> <textarea name="what_doing" class="govuk-textarea" id="textarea-a367d1cf" rows="3" spellcheck="true" aria-describedby="feedback_explanation"> </textarea> </div> <div class="gem-c-textarea govuk-form-group govuk-!-margin-bottom-6"> <label for="textarea-36fe2330" class="gem-c-label govuk-label">What went wrong?</label> <textarea name="what_wrong" class="govuk-textarea" id="textarea-36fe2330" rows="3" spellcheck="true"> </textarea> </div> <button class="gem-c-button govuk-button" type="submit">Send</button> </div> </div> </form> <script> document.addEventListener("DOMContentLoaded", function () { var input = document.querySelector("#giraffe"), form = document.querySelector("#something-is-wrong") form.addEventListener("submit", spamCapture); function spamCapture(e) { if (input.value.length !== 0) return; e.preventDefault(); } }); </script> <form action="/web/20221006143334/https://www.gov.uk/contact/govuk/email-survey-signup" id="page-is-not-useful" class="gem-c-feedback__form gem-c-feedback__form--email gem-c-feedback__js-show js-feedback-form" data-track-category="yesNoFeedbackForm" data-track-action="Send Form" method="post"> <button class="govuk-button govuk-button--secondary gem-c-feedback__close js-close-form" data-track-category="yesNoFeedbackForm" data-track-action="ffFormClose" aria-controls="page-is-not-useful" aria-expanded="true" hidden> Close </button> <div class="govuk-grid-row"> <div class="govuk-grid-column-two-thirds" id="survey-wrapper"> <div class="gem-c-feedback__error-summary js-errors" tabindex="-1" hidden></div> <input name="email_survey_signup[survey_id]" type="hidden" value="footer_satisfaction_survey"> <input name="email_survey_signup[survey_source]" type="hidden" value="/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment"> <h3 class="gem-c-feedback__form-heading">Help us improve GOV.UK</h3> <p id="survey_explanation" class="gem-c-feedback__form-paragraph">To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.</p> <div class="govuk-form-group"> <label for="input-80bbc13b" class="gem-c-label govuk-label">Email address</label> <input aria-describedby="survey_explanation" autocomplete="email" class="gem-c-input govuk-input" id="input-80bbc13b" name="email_survey_signup[email_address]" spellcheck="false" type="email"> </div> <button class="gem-c-button govuk-button" type="submit">Send me the survey</button> </div> </div> </form> </div> </div> <footer class="gem-c-layout-footer govuk-footer gem-c-layout-footer--border" role="contentinfo"> <div class="govuk-width-container"> <div class="govuk-footer__navigation" data-module="gem-track-click" data-track-links-only> <div class="govuk-grid-column-two-thirds govuk-!-display-none-print"> <h2 class="govuk-footer__heading govuk-heading-m">Topics</h2> <ul class="govuk-footer__list govuk-footer__list--columns-2"> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/benefits" data-track-options="{"dimension29":"Benefits"}" href="/web/20221006143334/https://www.gov.uk/browse/benefits">Benefits</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/births-deaths-marriages" data-track-options="{"dimension29":"Births, death, marriages and care"}" href="/web/20221006143334/https://www.gov.uk/browse/births-deaths-marriages">Births, death, marriages and care</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/business" data-track-options="{"dimension29":"Business and self-employed"}" href="/web/20221006143334/https://www.gov.uk/browse/business">Business and self-employed</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/childcare-parenting" data-track-options="{"dimension29":"Childcare and parenting"}" href="/web/20221006143334/https://www.gov.uk/browse/childcare-parenting">Childcare and parenting</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/citizenship" data-track-options="{"dimension29":"Citizenship and living in the UK"}" href="/web/20221006143334/https://www.gov.uk/browse/citizenship">Citizenship and living in the UK</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/cost-of-living" data-track-options="{"dimension29":"Cost of living support"}" href="/web/20221006143334/https://www.gov.uk/cost-of-living">Cost of living support</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/justice" data-track-options="{"dimension29":"Crime, justice and the law"}" href="/web/20221006143334/https://www.gov.uk/browse/justice">Crime, justice and the law</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/disabilities" data-track-options="{"dimension29":"Disabled people"}" href="/web/20221006143334/https://www.gov.uk/browse/disabilities">Disabled people</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/driving" data-track-options="{"dimension29":"Driving and transport"}" href="/web/20221006143334/https://www.gov.uk/browse/driving">Driving and transport</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/education" data-track-options="{"dimension29":"Education and learning"}" href="/web/20221006143334/https://www.gov.uk/browse/education">Education and learning</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/employing-people" data-track-options="{"dimension29":"Employing people"}" href="/web/20221006143334/https://www.gov.uk/browse/employing-people">Employing people</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/environment-countryside" data-track-options="{"dimension29":"Environment and countryside"}" href="/web/20221006143334/https://www.gov.uk/browse/environment-countryside">Environment and countryside</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/housing-local-services" data-track-options="{"dimension29":"Housing and local services"}" href="/web/20221006143334/https://www.gov.uk/browse/housing-local-services">Housing and local services</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/tax" data-track-options="{"dimension29":"Money and tax"}" href="/web/20221006143334/https://www.gov.uk/browse/tax">Money and tax</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/abroad" data-track-options="{"dimension29":"Passports, travel and living abroad"}" href="/web/20221006143334/https://www.gov.uk/browse/abroad">Passports, travel and living abroad</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/visas-immigration" data-track-options="{"dimension29":"Visas and immigration"}" href="/web/20221006143334/https://www.gov.uk/browse/visas-immigration">Visas and immigration</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="topicsLink" data-track-label="/browse/working" data-track-options="{"dimension29":"Working, jobs and pensions"}" href="/web/20221006143334/https://www.gov.uk/browse/working">Working, jobs and pensions</a> </li> </ul> </div> <div class="govuk-grid-column-one-third govuk-!-display-none-print"> <h2 class="govuk-footer__heading govuk-heading-m">Government activity</h2> <ul class="govuk-footer__list govuk-footer__list--columns-1"> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="governmentactivityLink" data-track-label="/government/organisations" data-track-options="{"dimension29":"Departments"}" href="/web/20221006143334/https://www.gov.uk/government/organisations">Departments</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="governmentactivityLink" data-track-label="/search/news-and-communications" data-track-options="{"dimension29":"News"}" href="/web/20221006143334/https://www.gov.uk/search/news-and-communications">News</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="governmentactivityLink" data-track-label="/search/guidance-and-regulation" data-track-options="{"dimension29":"Guidance and regulation"}" href="/web/20221006143334/https://www.gov.uk/search/guidance-and-regulation">Guidance and regulation</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="governmentactivityLink" data-track-label="/search/research-and-statistics" data-track-options="{"dimension29":"Research and statistics"}" href="/web/20221006143334/https://www.gov.uk/search/research-and-statistics">Research and statistics</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="governmentactivityLink" data-track-label="/search/policy-papers-and-consultations" data-track-options="{"dimension29":"Policy papers and consultations"}" href="/web/20221006143334/https://www.gov.uk/search/policy-papers-and-consultations">Policy papers and consultations</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="governmentactivityLink" data-track-label="/search/transparency-and-freedom-of-information-releases" data-track-options="{"dimension29":"Transparency"}" href="/web/20221006143334/https://www.gov.uk/search/transparency-and-freedom-of-information-releases">Transparency</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="governmentactivityLink" data-track-label="/government/how-government-works" data-track-options="{"dimension29":"How government works"}" href="/web/20221006143334/https://www.gov.uk/government/how-government-works">How government works</a> </li> <li class="govuk-footer__list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="governmentactivityLink" data-track-label="/government/get-involved" data-track-options="{"dimension29":"Get involved"}" href="/web/20221006143334/https://www.gov.uk/government/get-involved">Get involved</a> </li> </ul> </div> </div> <hr class="govuk-footer__section-break"> <div class="govuk-footer__meta"> <div class="govuk-footer__meta-item govuk-footer__meta-item--grow"> <h2 class="govuk-visually-hidden">Support links</h2> <ul class="govuk-footer__inline-list govuk-!-display-none-print" data-module="gem-track-click" data-track-links-only> <li class="govuk-footer__inline-list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="supportLink" data-track-label="/help" data-track-options="{"dimension29":"Help"}" href="/web/20221006143334/https://www.gov.uk/help">Help</a> </li> <li class="govuk-footer__inline-list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="supportLink" data-track-label="/help/privacy-notice" data-track-options="{"dimension29":"Privacy"}" href="/web/20221006143334/https://www.gov.uk/help/privacy-notice">Privacy</a> </li> <li class="govuk-footer__inline-list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="supportLink" data-track-label="/help/cookies" data-track-options="{"dimension29":"Cookies"}" href="/web/20221006143334/https://www.gov.uk/help/cookies">Cookies</a> </li> <li class="govuk-footer__inline-list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="supportLink" data-track-label="/help/accessibility-statement" data-track-options="{"dimension29":"Accessibility statement"}" href="/web/20221006143334/https://www.gov.uk/help/accessibility-statement">Accessibility statement</a> </li> <li class="govuk-footer__inline-list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="supportLink" data-track-label="/contact" data-track-options="{"dimension29":"Contact"}" href="/web/20221006143334/https://www.gov.uk/contact">Contact</a> </li> <li class="govuk-footer__inline-list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="supportLink" data-track-label="/help/terms-conditions" data-track-options="{"dimension29":"Terms and conditions"}" href="/web/20221006143334/https://www.gov.uk/help/terms-conditions">Terms and conditions</a> </li> <li class="govuk-footer__inline-list-item"> <a class="govuk-footer__link" lang="cy" data-track-category="footerClicked" data-track-action="supportLink" data-track-label="/cymraeg" data-track-options="{"dimension29":"Rhestr o Wasanaethau Cymraeg"}" href="/web/20221006143334/https://www.gov.uk/cymraeg">Rhestr o Wasanaethau Cymraeg</a> </li> <li class="govuk-footer__inline-list-item"> <a class="govuk-footer__link" data-track-category="footerClicked" data-track-action="supportLink" data-track-label="/government/organisations/government-digital-service" data-track-options="{"dimension29":"Government Digital Service"}" href="/web/20221006143334/https://www.gov.uk/government/organisations/government-digital-service">Government Digital Service</a> </li> </ul> <svg aria-hidden="true" focusable="false" class="govuk-footer__licence-logo" xmlns="http://www.w3.org/2000/svg" viewbox="0 0 483.2 195.7" height="17" width="41"> <path fill="currentColor" d="M421.5 142.8V.1l-50.7 32.3v161.1h112.4v-50.7zm-122.3-9.6A47.12 47.12 0 0 1 221 97.8c0-26 21.1-47.1 47.1-47.1 16.7 0 31.4 8.7 39.7 21.8l42.7-27.2A97.63 97.63 0 0 0 268.1 0c-36.5 0-68.3 20.1-85.1 49.7A98 98 0 0 0 97.8 0C43.9 0 0 43.9 0 97.8s43.9 97.8 97.8 97.8c36.5 0 68.3-20.1 85.1-49.7a97.76 97.76 0 0 0 149.6 25.4l19.4 22.2h3v-87.8h-80l24.3 27.5zM97.8 145c-26 0-47.1-21.1-47.1-47.1s21.1-47.1 47.1-47.1 47.2 21 47.2 47S123.8 145 97.8 145"></path> </svg> <span class="govuk-footer__licence-description" data-module="gem-track-click" data-track-action="copyrightLink" data-track-category="footerClicked" data-track-label="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/" data-track-options="{"dimension29": "Open Government Licence v3.0"}" data-track-links-only> All content is available under the <a class="govuk-footer__link" href="http://web.archive.org/web/20221006143334/https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/" rel="license">Open Government Licence v3.0</a>, except where otherwise stated </span> </div> <div class="govuk-footer__meta-item" data-module="gem-track-click" data-track-action="copyrightLink" data-track-category="footerClicked" data-track-label="https://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/uk-government-licensing-framework/crown-copyright/" data-track-options="{"dimension29": "© Crown copyright"}" data-track-links-only> <a class="govuk-footer__link govuk-footer__copyright-logo" href="http://web.archive.org/web/20221006143334/https://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/uk-government-licensing-framework/crown-copyright/">© Crown copyright</a> </div> </div> </div> </footer> <script src="http://web.archive.org/web/20221006143334js_/https://www.gov.uk/assets/static/application-087272cd04e26ba8d2c7c0ccef5db8dcc67495fdae7ef356f838d916abeda4c6.js"></script> <script src="/web/20221006143334js_/https://www.gov.uk/assets/government-frontend/application-cc1b87cb7f7a7266f46b044ca2fdbe06fe48f196c15b5dbc53f62ca09af57aba.js"></script><script type="application/ld+json"> { "@context": "http://web.archive.org/web/20221006143334/http://schema.org", "@type": "FAQPage", "mainEntityOfPage": { "@type": "WebPage", "@id": "http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment" }, "name": "Decision on Evusheld as a COVID-19 treatment", "datePublished": "2022-10-06T13:00:02.000+00:00", "dateModified": "2022-10-04T14:04:11.000+00:00", "text": null, "publisher": { "@type": "Organization", "name": "GOV.UK", "url": "http://web.archive.org/web/20221006143334/https://www.gov.uk", "logo": { "@type": "ImageObject", "url": "http://web.archive.org/web/20221006143334/https://www.gov.uk/assets/government-frontend/govuk_publishing_components/govuk-logo-73b5a4056ffe9988d02c728b56fe9fe7f90bb822322a5f6183ccbb92a99b019a.png" } }, "image": [ "http://web.archive.org/web/20221006143334/https://www.gov.uk/assets/government-frontend/govuk_publishing_components/govuk-schema-placeholder-1x1-bf9e64d759af6dfd93bede8168f3087a329f405b382aff36747db0db4b7b23e9.png", "http://web.archive.org/web/20221006143334/https://www.gov.uk/assets/government-frontend/govuk_publishing_components/govuk-schema-placeholder-4x3-13093f053c15f613acd827aff27cac83d3fab452947cbcae4c7b706dadf2f7f2.png", "http://web.archive.org/web/20221006143334/https://www.gov.uk/assets/government-frontend/govuk_publishing_components/govuk-schema-placeholder-16x9-4233cd42671827e266e284c4d5ae68fb600bd9f9e35dda663ccabbc2b6ab7ec3.png" ], "author": { "@type": "Organization", "name": "Department of Health and Social Care", "url": "http://web.archive.org/web/20221006143334/https://www.gov.uk/government/organisations/department-of-health-and-social-care" }, "mainEntity": [ { "@type": "Question", "name": "Government decision on Evusheld", "url": "http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment#government-decision-on-evusheld", "acceptedAnswer": { "@type": "Answer", "url": "http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment#government-decision-on-evusheld", "text": "\u003cp\u003eThank you for your letters of \u003ca rel=\"external\" href=\"https://bloodcancer.org.uk/news/leading-charities-and-clinicians-urge-government-to-secure-evusheld/\" class=\"govuk-link\"\u003e28 July\u003c/a\u003e and \u003ca rel=\"external\" href=\"https://media.bloodcancer.org.uk/documents/Evusheld_Letter_to_Barclay_23.08.22.pdf\" class=\"govuk-link\"\u003e23 August 2022\u003c/a\u003e on Evusheld.\u003c/p\u003e\u003cp\u003eI understand your concerns and would like to assure you that government efforts remain absolutely focused on protecting the most vulnerable, including through prioritised access to vaccines, treatments and testing.\u003c/p\u003e\u003cp\u003eThe expert panel who advises government has made clear that there is insufficient evidence available at this time to support procurement and deployment of Evusheld through emergency procedures.\u003c/p\u003e\u003cp\u003eWhen the Medicines and Healthcare products Regulatory Agency (\u003cabbr title=\"Medicines and Healthcare products Regulatory Agency\"\u003eMHRA\u003c/abbr\u003e) gave conditional marketing authorisation to Evusheld on 17 March 2022, following trials conducted during the Delta wave of the coronavirus (COVID-19) pandemic, it noted a lack of data regarding dose and efficacy against Omicron.\u003c/p\u003e\u003cp\u003eA number of other countries’ regulatory authorities, including the European Medicines Agency and the US Food and Drug Administration, have noted similar issues, although many of those countries who had already procured Evusheld have decided to continue using it, in most cases doubling the dose to 600mg.\u003c/p\u003e\u003cp\u003eThere have been similar concerns about the effectiveness of other monoclonal antibodies to emerging COVID-19 variants, on the basis of in vitro (laboratory) testing, leading to appropriate re-evaluation prior to recommendation for widespread deployment or continuation of use. In some instances, the in vitro data has been so unequivocal in demonstrating lack of effectiveness that a product has been promptly withdrawn – in the case of Evusheld, a number of different groups have conducted laboratory tests with different Omicron sub-variants and there is ongoing uncertainty about how these results might translate to clinical effectiveness.\u003c/p\u003e\u003cp\u003eTo address your specific questions, the decision has been made not to procure Evusheld at this time drawing on expert advice from the \u003ca rel=\"external\" href=\"https://www.nice.org.uk/covid-19/rapid-c19\" class=\"govuk-link\"\u003eresearch to access pathway for investigational drugs for COVID-19 (\u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e)\u003c/a\u003e Oversight Group and a UK national expert policy working group as well as Department of Health and Social Care (\u003cabbr title=\"Department of Health and Social Care\"\u003eDHSC\u003c/abbr\u003e) officials, all of whom have collectively concluded that there is insufficient evidence of benefit to recommend deployment at this time. In their expert advice, \u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e note that:\u003c/p\u003e\u003cblockquote\u003e\n \u003cp class=\"last-child\"\u003ethe risks of proceeding to patient access are considered to outweigh the risks of not providing this treatment in the current pandemic context.\u003c/p\u003e\n\u003c/blockquote\u003e\u003cp\u003eMore detail on \u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e can be found in Annex A.\u003c/p\u003e\u003cp\u003e\u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e has considered the evidence base for Evusheld 11 times in 18 months, starting in February 2021, and is keeping it under active review, including through monitoring the emerging data. They have considered a full range of evidence, including clinical trial data, in vitro analysis and all the observational studies in the appendix to your letter of 23 August 2022.\u003c/p\u003e\u003cp\u003eAs the authors note themselves, there are limitations to these studies.\u003c/p\u003e\u003cp\u003eFor example, Young-Xu and others state:\u003c/p\u003e\u003cblockquote\u003e\n \u003cp class=\"last-child\"\u003eresults may not be generalizable to a larger population of patients.\u003c/p\u003e\n\u003c/blockquote\u003e\u003cp\u003eKertes and others state:\u003c/p\u003e\u003cblockquote\u003e\n \u003cp class=\"last-child\"\u003ethe study did not take into account differences between the 2 groups regarding other antiviral treatments available, such as nirmatrelvir, that may also affect severe disease prevalence.\u003c/p\u003e\n\u003c/blockquote\u003e\u003cp\u003eAnd Jurdi and others state:\u003c/p\u003e\u003cblockquote\u003e\n \u003cp class=\"last-child\"\u003eThe limitations of our study include its observational nature, retrospective design, lack of ability to detect asymptomatic breakthrough infections and possible differences between the tixagevimab/cilgavimab and control groups that could have influenced the rate of breakthrough infection.\u003c/p\u003e\n\u003c/blockquote\u003e\u003cp\u003eIn addition to the inherent limitations of observational data – particularly on small sample sizes – it should also be noted that most of these studies are pre-prints (therefore have not been scrutinised through peer review). There are also concerns with the methodology of a number of studies, as it is not clear that the comparator group is adequately matched (such that the Evusheld group may be at inherently lower risk of adverse outcomes), or where the follow-up period is substantially shorter for the Evusheld group compared with the control group (such that the Evusheld group would have had a shorter time to experience a COVID-19 infection).\u003c/p\u003e\u003cp\u003eSo, while some of the findings may appear encouraging, the view from our experts remains that the methodological and reporting limitations of these papers means there is insufficient evidence from the clinical data to recommend deployment at this time.\u003c/p\u003e\u003cp\u003eThe Chief Medical Officer is content that the correct process for providing clinical advice has been followed and agrees that Evusheld should now be appraised by the National Institute for Health and Care Excellence (\u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e) following the usual process for drugs being made available to NHS patients.\u003c/p\u003e\u003cp\u003eIn terms of the patients who stand to benefit from a safe and effective prophylactic, your letter refers to 500,000 immunosuppressed people in the UK. Notwithstanding the questions on efficacy and duration of effect, it is highly unlikely that supply could be made available to the UK for all these patients in autumn or winter 2022, particularly as doubling the dose to 600mg is recommended for use against Omicron.\u003c/p\u003e\u003cp\u003eMoreover, it is also unlikely to be suitable or needed for this size of cohort. Evidence shows that different patient groups with immunosuppression have different levels of vaccine response. Identifying the correct cohorts (for example those with unpredictable, low or no antibody response) would be essential, even if questions on effectiveness were sufficiently answered.\u003c/p\u003e\u003cp\u003eEvusheld is not necessary for those patients who have a protective antibody response to COVID-19 vaccination. In order to understand better who within this group mounts a vaccine response, we are exploring the possibility of piloting a programme to test antibody levels in immunosuppressed patients. This could help develop a more accurate understanding of potential cohorts for prophylactic treatments in future and provide reassurance to some patients by identifying any who have mounted a protective antibody response following vaccination. Officials will follow up with patient groups separately to seek input into the development of this potential programme.\u003c/p\u003e\u003cp\u003eIn order to gain further evidence, our clinical advisers have also recommended a trial is considered as a route to answering outstanding questions on the link between in vitro tests and clinical outcomes for current and future variants, which is currently not known, together with evaluating the effectiveness and safety of a dose of 600mg, as this was not tested in the randomised controlled trials.\u003c/p\u003e\u003cp\u003eI personally met senior AstraZeneca leaders on Thursday 18 August 2022, and the \u003cabbr title=\"Department of Health and Social Care\"\u003eDHSC\u003c/abbr\u003e Chief Scientific Adviser has had frequent discussions with science leaders in AstraZeneca, including a meeting on Friday 26 August 2022 to discuss data from existing observational studies in detail. We remain committed to close working with the company, and I greatly value the continued partnership we share with AstraZeneca and recognise the very positive impact they have made throughout the pandemic and beyond.\u003c/p\u003e\u003cp\u003eYours,\u003c/p\u003e\u003cp\u003eRt Hon Steve Barclay MP\u003c/p\u003e" } }, { "@type": "Question", "name": "Annex A", "url": "http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment#annex-a", "acceptedAnswer": { "@type": "Answer", "url": "http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment#annex-a", "text": "\u003ch3 id=\"about-rapid-c-19\"\u003eAbout \u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e\n\u003c/h3\u003e\u003cp\u003e\u003ca rel=\"external\" href=\"https://www.nice.org.uk/covid-19/rapid-c19\" class=\"govuk-link\"\u003e\u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e\u003c/a\u003e is a multi-agency initiative set up in response to the pandemic that aims to get treatments for COVID-19 to NHS patients quickly and safely. Its membership includes the UK’s main healthcare agencies including:\u003c/p\u003e\u003cul\u003e\n \u003cli\u003e\u003cabbr title=\"Medicines and Healthcare products Regulatory Agency\"\u003eMHRA\u003c/abbr\u003e\u003c/li\u003e\n \u003cli\u003e\u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e\u003c/li\u003e\n \u003cli\u003eNHS England (\u003cabbr title=\"NHS England\"\u003eNHSE\u003c/abbr\u003e) and the NHS\u003c/li\u003e\n \u003cli\u003eNational Institute for Health Research (\u003cabbr title=\"National Institute for Health Research\"\u003eNIHR\u003c/abbr\u003e)\u003c/li\u003e\n \u003cli\u003ethe devolved governments\u003c/li\u003e\n\u003c/ul\u003e\u003cp\u003eThe NHS had overall responsibility for establishing \u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e, and \u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e chairs the Senior \u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e Oversight Group and provides secretariat support.\u003c/p\u003e\u003cp\u003eAs of June 2022, \u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e had around 90 topics in active monitoring and the oversight group has considered the evidence in detail for those drugs that have evidence of benefit, since it was stood up in April 2020. Of these, 9 have led to a positive recommendation to the 4 UK Chief Medical Officers that direct deployment outside of the more normal processes should be considered.\u003c/p\u003e\u003ch3 id=\"reporting\"\u003eReporting\u003c/h3\u003e\u003cp\u003e\u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e is a multi-agency initiative including \u003cabbr title=\"National Institute for Health Research\"\u003eNIHR\u003c/abbr\u003e, \u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e, \u003cabbr title=\"Medicines and Healthcare products Regulatory Agency\"\u003eMHRA\u003c/abbr\u003e, \u003cabbr title=\"NHS England\"\u003eNHSE\u003c/abbr\u003e and representatives from the devolved governments. The agencies aim to ensure safe and timely patient access to treatments that show evidence of benefit in preventing and treating COVID-19.\u003c/p\u003e\u003cp\u003eWhere good evidence of efficacy of a treatment is sufficient for further action to be taken, the oversight group’s assessment of the evidence and suggested next steps are summarised in a briefing to the Chief Medical Officer.\u003c/p\u003e\u003ch3 id=\"expert-working-group\"\u003eExpert working group\u003c/h3\u003e\u003cp\u003eIn parallel to the formation of \u003cabbr title=\"research to access pathway for investigational drugs for COVID-19\"\u003eRAPID C-19\u003c/abbr\u003e, \u003cabbr title=\"NHS England\"\u003eNHSE\u003c/abbr\u003e extended its existing national clinical policy-making process to cover COVID-19 therapeutics. As part of this process, a national expert working group (\u003cabbr title=\"expert working group\"\u003eEWG\u003c/abbr\u003e) was created to support development of a national clinical policy with a focus on clinical effectiveness and eligibility criteria.\u003c/p\u003e\u003cp\u003eAn \u003cabbr title=\"expert working group\"\u003eEWG\u003c/abbr\u003e is convened to develop a national clinical policy for a specific drug or sometimes to provide further relevant advice. The \u003cabbr title=\"expert working group\"\u003eEWG\u003c/abbr\u003e is chaired by a senior NHS staff member, and the membership includes UK-wide national experts and frontline clinicians. Officials from the devolved governments are also involved throughout.\u003c/p\u003e\u003cp\u003eEWGs have focused on therapeutic agents but, more recently, have also considered prophylactic agents.\u003c/p\u003e" } }, { "@type": "Question", "name": "Annex B", "url": "http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment#annex-b", "acceptedAnswer": { "@type": "Answer", "url": "http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment#annex-b", "text": "\u003ch3 id=\"nice-appraisal-process\"\u003e\n\u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e appraisal process\u003c/h3\u003e\u003cp\u003e\u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e provides evidence-based, rigorous evaluation of the clinical and cost effectiveness of medicines for use in the NHS.\u003c/p\u003e\u003cp\u003e\u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e began consulting stakeholders on the draft scope for an evaluation of the clinical and cost effectiveness of Evusheld for preventing COVID-19 in July 2022, and it was formally referred to \u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e by \u003cabbr title=\"Department of Health and Social Care\"\u003eDHSC\u003c/abbr\u003e on 10 August 2022. The \u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e appraisal has begun this month with draft guidance expected in April 2023.\u003c/p\u003e\u003cp\u003e\u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e, in discussion with AstraZeneca, has taken steps to expedite the appraisal process by bringing forward the deadline for the company’s evidence submission so that it is able to issue guidance to the NHS as quickly as possible.\u003c/p\u003e\u003cp\u003e\u003ca rel=\"external\" href=\"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/process\" class=\"govuk-link\"\u003eLearn more about the \u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e technology appraisal process.\u003c/a\u003e\u003c/p\u003e\u003cp\u003eMore detailed information on the Evusheld appraisal process will be provided on \u003cabbr title=\"National Institute for Health and Care Excellence\"\u003eNICE\u003c/abbr\u003e’s website shortly.\u003c/p\u003e" } } ] } </script><script type="application/ld+json"> { "@context": "http://web.archive.org/web/20221006143334/http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "name": "Home", "@id": "http://web.archive.org/web/20221006143334/https://www.gov.uk/" } }, { "@type": "ListItem", "position": 2, "item": { "name": "Coronavirus (COVID-19)", "@id": "http://web.archive.org/web/20221006143334/https://www.gov.uk/coronavirus-taxon" } }, { "@type": "ListItem", "position": 3, "item": { "name": "Health and wellbeing during coronavirus", "@id": "http://web.archive.org/web/20221006143334/https://www.gov.uk/coronavirus-taxon/health-and-wellbeing" } }, { "@type": "ListItem", "position": 4, "item": { "name": "Decision on Evusheld as a coronavirus (COVID-19) treatment: letter to patient groups", "@id": "http://web.archive.org/web/20221006143334/https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups" } } ] } </script> </body> </html>

CINXE.COM